Cited by 591Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Ribas, Antoni, Camacho, Luis H., Lopez-Berestein, Gabriel, Pavlov, Dmitri, Bulanhagui, Cecile A., Millham, Robert, Comin-Anduix, Begoña, Reuben, James M., Seja, Elisabeth, Parker, Charla A., Sharma, Amarnath, Glaspy, John A., Gomez-Navarro, Jesus·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.01.109

Open this paper in CoChat — free account

Abstract

Purpose: Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance leading to effective immune responses to cancer in humans. A phase I trial was conducted to test the safety of CP-675,206. Patients and Methods: Thirty-nine patients with solid malignancies (melanoma, n = 34; renal cell, n = 4; colon, n = 1) received an intravenous (IV) infusion of CP-675,206 at seven dose levels. The primary objective was to determine the maximum-tolerated dose and the recommended phase II dose. Results: Dose-limiting toxicities and autoimmune phenomena included diarrhea, dermatitis, vitiligo, panhypopituitarism and hyperthyroidism. Two patients experienced complete responses (maintained for 34+ and 25+ months), and there were two partial responses (26+ and 25+ months) among 29 patients with measurable melanoma. There have been no relapses thus far after objective response to therapy. Four other patients had stable disease at end of study evaluation (16, 7, 7, and 4 months). Additionally, five patients had extended periods without disease progression (36+, 35+, 26+, 24+, and 23+ months) after local treatment of progressive metastases. Longer systemic exposure to CP-675,206 achieved in higher dose cohorts predicted for a higher probability of response. Conclusion: CP-675,206 can be administered safely to humans as a single IV dose up to 15 mg/kg, resulting in breaking of peripheral immune tolerance to self-tissues and antitumor activity in melanoma.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.01.109

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,204
Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 101–200 of 591

Orchestrating immune check-point blockade for cancer immunotherapy in combinations
Perez‐Gracia, J. L., Labiano, S., Rodriguez-Ruiz, M. E., Sanmamed, M. F., & Melero, I. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.002 · Cited by 131
Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
Ribas, A. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.010 · Cited by 134
Self-citation
What Is the Role of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 128
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Hamid, O., & Carvajal, R. D. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.770836 · Cited by 123
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Girotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 131
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma
Bajor, D. L., Mick, R., Riese, M. J., Huang, A. C., Sullivan, B. J., Richman, L. P., Torigian, D. A., George, S. M., Stelekati, E., Chen, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1468956 · Cited by 123
Dendritic cell vaccines in melanoma: From promise to proof?
Lesterhuis, W. J., Aarntzen, E. H. J. G., de Vries, I. J. M., Schuurhuis, D. H., Figdor, C. G., Adema, G. J., & Punt, C. J. A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.007 · Cited by 119
Targeted Therapies to Improve Tumor Immunotherapy
Begley, J. L., & Ribas, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4804 · Cited by 118
Self-citation
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
Yano, H., Andrews, L. P., Workman, C. J., & Vignali, D. A. A. (2019) · Immunology · doi:10.1111/imm.13067 · Cited by 116
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
Torino, F., Barnabei, A., Paragliola, R. M., Marchetti, P., Salvatori, R., & Corsello, S. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0434 · Cited by 117
CTLA4 Expression Is an Indicator and Regulator of Steady-State CD4+FoxP3+ T Cell Homeostasis
Tang, A. L., Teijaro, J. R., Njau, M. N., Chandran, S. S., Azimzadeh, A. M., Nadler, S. G., Rothstein, D. M., & Färber, D. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1806 · Cited by 123
Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy
Cerezo, M., & Rocchi, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03175-5 · Cited by 118
Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1
Nicholaou, T., Ebert, L. M., Davis, I. D., Robson, N. C., Klein, O., Maraskovsky, E., Chen, W., & Cebon, J. S. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01446.x · Cited by 112
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107
Checkpoint Inhibitor–Induced Colitis
Bellaguarda, E., & Hanauer, S. B. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000497 · Cited by 107
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Hunter, G. R. W., Voll, C., & Robinson, C. A. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007939 · Cited by 105
Hitting the Target: How T Cells Detect and Eliminate Tumors
Zamora, A. E., Crawford, J. C., & Thomas, P. G. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701413 · Cited by 109
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction
Miller, J. S., Warren, E. H., van den Brink, M. R. M., Ritz, J., Shlomchik, W. D., Murphy, W. J., Barrett, A. J., Kolb, H. J., Giralt, S., Bishop, M. R., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.02.005 · Cited by 108
CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
Menard, C., Ghiringhelli, F., Roux, S., Chaput, N., Mateus, C., Grohmann, U., Caillat‐Zucman, S., Zitvogel, L., & Robert, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4797 · Cited by 106
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
Postel-Vinay, S. C., Aspeslagh, S., Lanoy, É., Robert, C., Soria, J., & Marabelle, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv550 · Cited by 108
A phase 2 study of tremelimumab in patients with advanced uveal melanoma
Joshua, A. M., Monzon, J. G., Mihalcioiu, C. L. D., Hogg, D., Smylie, M., & Cheng, T. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000175 · Cited by 105
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 108
Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab
Ribas, A., Benz, M., Allen-Auerbach, M., Radu, C. G., Chmielowski, B., Seja, E., Williams, J. L., Gómez-Navarro, J., McCarthy, T. J., & Czernin, J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.070946 · Cited by 103
Self-citation
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Weber, J. S. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-16 · Cited by 103
Diet, Microbiome, and Cancer Immunotherapy—A Comprehensive Review
Szczyrek, M., Bitkowska, P., Chunowski, P., Czuchryta, P., Krawczyk, P. A., & Milanowski, J. (2021) · Nutrients · doi:10.3390/nu13072217 · Cited by 104
GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men
Hege, K. M., Jooss, K. U., & Pardoll, D. M. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992498 · Cited by 101
Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., Jackson, H. M., Dimopoulos, N., Tan, B. S., Hoos, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2424 · Cited by 100
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · BioMed Research International · doi:10.1155/2012/926321 · Cited by 103
Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Ma, Z., Li, W., Yoshiya, S., Xu, Y., Hata, M., El‐Darawish, Y., Markova, T., Yamanishi, K., Yamanishi, H., Tahara, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1655 · Cited by 99
Immune checkpoint inhibitors in renal cell carcinoma
Ross, K., & Jones, R. J. (2017) · Clinical Science · doi:10.1042/cs20160894 · Cited by 100
MicroRNA Profile of Circulating CD4-positive Regulatory T Cells in Human Adults and Impact of Differentially Expressed MicroRNAs on Expression of Two Genes Essential to Their Function
Fayyad‐Kazan, H., Rouas, R., Fayyad‐Kazan, M., Badran, R., Zein, N. E., Lewalle, P., Najar, M., Hamade, E., Jebbawi, F., Merimi, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.337154 · Cited by 104
Immune Checkpoint Blockade
Naidoo, J., Page, D. B., & Wolchok, J. D. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.002 · Cited by 102
PD-L1 Blockade for Cancer Treatment: MEDI4736
Ibrahim, R. A., Stewart, R. A., & Shalabi, A. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.007 · Cited by 95
The complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 93
From cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 91
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
Kyte, J. A., & Gaudernack, G. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0161-7 · Cited by 90
Comparative methodologies of regulatory T cell depletion in a murine melanoma model
Matsushita, N., Pilon‐Thomas, S., Martin, L. M., & Riker, A. I. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.01.012 · Cited by 89
Melanoma stem cells: not rare, but well done
Girouard, S. D., & Murphy, G. F. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.50 · Cited by 92
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
Jure‐Kunkel, M., Masters, G. R., Girit, E., Dito, G., Lee, F. Y., Hunt, J. T., & Humphrey, R. W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1451-5 · Cited by 86
Human Monoclonal Antibodies from Transgenic Mice
Lönberg, N. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 90
Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
CTLA-4 blockade: therapeutic potential in cancer treatments
Tarhini, A. A. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s4833 · Cited by 84
Tremelimumab: research and clinical development
Ibarrondo, F. J., Comin-Anduix, B., & Escuin-Ordinas, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s65802 · Cited by 86
Self-citation
Cancer vaccines: on the threshold of success
Emens, L. A. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.295 · Cited by 83
Effect of cancer treatment on hypothalamic–pituitary function
Crowne, E. C., Gleeson, H. K., Benghiat, H., Sanghera, P., & Toogood, A. A. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00008-x · Cited by 82
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab
Eroglu, Z., Kim, D. W., Wang, X., Camacho, L. H., Chmielowski, B., Seja, E., Villanueva, A., Ruchalski, K. L., Glaspy, J. A., Kim, K. B., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.012 · Cited by 87
Self-citation
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
Comı́n-Anduix, B., Lee, Y., Jalil, J., Algazi, A. P., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-22 · Cited by 82
Self-citation
Immunotherapy for Advanced Melanoma
Fang, L., Lonsdorf, A. S., & Hwang, S. T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.101 · Cited by 85
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma
Atkins, M. B., Sosman, J. A., Agarwala, S. S., Logan, T. F., Clark, J. I., Ernstoff, M. S., Lawson, D., Dutcher, J. P., Weiss, G. R., Curti, B. D., et al. (2008) · Cancer · doi:10.1002/cncr.23805 · Cited by 80
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
Desnoyer, A., Broutin, S., Delahousse, J., Maritaz, C., Blondel, L., Mir, O., Chaput, N., & Paci, A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.003 · Cited by 79
Dendritic Cells in Cancer Immunotherapy
Vulink, A. J. E., Radford, K. J., Melief, C. J. M., & Hart, D. N. J. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(07)99006-5 · Cited by 80
Immunotherapy for Melanoma: Current Status and Perspectives
Alexandrescu, D. T., Ichim, T. E., Riordan, N. H., Marincola, F. M., Nardo, A. D., Kabigting, F. D., & Dasanu, C. A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e032e8 · Cited by 80
Immune Checkpoint Inhibitors in NSCLC
Johnson, D. B., Rioth, M. J., & Horn, L. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0305-5 · Cited by 79
Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
Torino, F., Barnabei, A., Vecchis, L. D., Salvatori, R., & Corsello, S. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0404 · Cited by 79
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Ray, A., Williams, M. A., Meek, S. M., Bowen, R. C., Grossmann, K. F., Andtbacka, R. H. I., Bowles, T. L., Hyngstrom, J. R., Leachman, S. A., Grossman, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10453 · Cited by 79
The expression, function, and clinical relevance of B7 family members in cancer
Seliger, B., & Quandt, D. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1293-6 · Cited by 79
Immunogenic Cell Death Inducing Fluorinated Mitochondria‐Disrupting Helical Polypeptide Synergizes with PD‐L1 Immune Checkpoint Blockade
Jeong, S. D., Jung, B., Ahn, H. M., Lee, D., Ha, J., Noh, I., Yun, C., & Kim, Y. (2021) · Advanced Science · doi:10.1002/advs.202001308 · Cited by 78
Clinical Development of Immune Checkpoint Inhibitors
Ito, A., Kondo, S., Tada, K., & Kitano, S. (2015) · BioMed Research International · doi:10.1155/2015/605478 · Cited by 79
Tremelimumab: A Review of Development to Date in Solid Tumors
Tarhini, A. A. (2013) · Immunotherapy · doi:10.2217/imt.13.9 · Cited by 74
Update on anti-CTLA-4 antibodies in clinical trials
Langer, L., Clay, T. M., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1245 · Cited by 73
Colorectal cancer: the first neoplasia found to be under immunosurveillance and the last one to respond to immunotherapy?
Kroemer, G., Galluzzi, L., Zitvogel, L., & Fridman, W. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1058597 · Cited by 73
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Ascierto, P. A., & Kirkwood, J. M. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-62 · Cited by 73
Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go
Vasaturo, A., Blasio, S. D., Peeters, D. G. A., de Koning, C. C. H., de Vries, I. J. M., Figdor, C. G., & Hato, S. V. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00417 · Cited by 76
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.017 · Cited by 72
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells
Khan, S. S., Burt, D. J., Ralph, C., Thistlethwaite, F. C., Hawkins, R. E., & Elkord, E. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.09.011 · Cited by 72
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70
Melanoma immunology: past, present and future
Parmiani, G., Castelli, C., Santinami, M., & Rivoltini, L. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32801497d7 · Cited by 68
Design considerations for early-phase clinical trials of immune-oncology agents
Wages, N. A., Chiuzan, C. C., & Panageas, K. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0389-8 · Cited by 65
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
Millward, M., Underhill, C. R., Lobb, S., McBurnie, J., Meech, S. J., Gómez-Navarro, J., Marshall, M. A., Huang, B., & Mather, C. B. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.227 · Cited by 67
Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Associations of health literacy with self-management behaviours and health outcomes in chronic kidney disease: a systematic review
Billany, R. E., Thopte, A., Adenwalla, S. F., March, D. S., Burton, J. O., & Graham-Brown, M. P. M. (2023) · Journal of Nephrology · doi:10.1007/s40620-022-01537-0 · Cited by 65
Therapeutic vaccines in solid tumours: Can they be harmful?
Eggermont, A. M. M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.004 · Cited by 65
Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma
Tarhini, A. A., Leng, S., Moschos, S. J., Yin, Y., Sander, C., Lin, Y., Gooding, W. E., & Kirkwood, J. M. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825481fe · Cited by 64
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
Schneider, H., & Rudd, C. E. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00619 · Cited by 65
Immunotherapy of melanoma
Haanen, J. B. A. G. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.013 · Cited by 64
The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience
Berman, D., Korman, A. J., Peck, R., Feltquate, D., Lönberg, N., & Canetta, R. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.017 · Cited by 65
Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
Lü, J., Li, L., Lan, Y., Liang, Y., & Meng, H. (2019) · Cancer Medicine · doi:10.1002/cam4.2661 · Cited by 63
Cytotoxic T-Lymphocyte–Associated Antigen-4
Hodi, F. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0813 · Cited by 63
Immunomodulatory therapy for melanoma: Ipilimumab and beyond
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.006 · Cited by 63
Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer
Groß, S., & Walden, P. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.11.012 · Cited by 60
Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease
Brichard, V. G., & Lejeune, D. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.951 · Cited by 59
Tremelimumab-Induced Graves Hyperthyroidism
Gan, E. H., Mitchell, A. L., Plummer, R., Pearce, S., & Perros, P. (2017) · European Thyroid Journal · doi:10.1159/000464285 · Cited by 58
Local delivery of low-dose anti–CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation
van Pul, K. M., Notohardjo, J. C. L., Fransen, M. F., Koster, B. D., Stam, A. G. M., Chondronasiou, D., Lougheed, S. M., Bakker, J., Kandiah, V., van den Tol, M. P., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn8097 · Cited by 58
CTLA-4 Blockade with Monoclonal Antibodies in Patients with Metastatic Cancer: Surgical Issues
Phan, G. Q., Weber, J. S., & Sondak, V. K. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0104-y · Cited by 58
Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor
Chiang, C. L.-L., Ledermann, J. A., Aitkens, E., Benjamin, E. O., Katz, D. R., & Chain, B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4899 · Cited by 59
Controlled Release of Antigen and Toll-like Receptor Ligands From PLGA Nanoparticles Enhances Immunogenicity
Cruz, L. J., Tacken, P. J., Eich, C., Rueda, F., Torensma, R., & Figdor, C. G. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0295 · Cited by 58
Autoimmunity and Immunotherapy for Cancer
Koon, H. B., & Atkins, M. B. (2006) · New England Journal of Medicine · doi:10.1056/nejme058307 · Cited by 58
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
Ribas, A. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-10 · Cited by 56
Self-citation
Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.
Hashash, J. G., Francis, F. F., & Farraye, F. A. (2021) · Europe PMC (PubMed Central) · Cited by 55
Stem cells and targeted approaches to melanoma cure
Murphy, G. F., Wilson, B. J., Girouard, S. D., Frank, N. Y., & Frank, M. H. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.10.003 · Cited by 56
Assessing oncologic benefit in clinical trials of immunotherapy agents
Hales, R. K., Banchereau, J., Ribas, A., Tarhini, A. A., Weber, J. S., Fox, B. A., & Drake, C. G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq048 · Cited by 55
Self-citation
Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?
Lorigan, P. C., Eisen, T. G., & Hauschild, A. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2007.00673.x · Cited by 53
Enhancing cancer vaccines with immunomodulators
Berinstein, N. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.043 · Cited by 55
Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies
Gray, J. C., French, R. R., James, S., Al‐Shamkhani, A., Johnson, P., & Glennie, M. J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838208 · Cited by 54
Immunotherapy of melanoma: a critical review of current concepts and future strategies
Riker, A. I., Radfar, S., Liu, S., Wang, Y., & Khong, H. T. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.345 · Cited by 53
Roadmap to a Better Therapeutic Tumor Vaccine
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992423 · Cited by 53
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
Ohue, Y., Kurose, K., Nozawa, R., Isobe, M., Nishio, Y., Tanaka, T., Doki, Y., Hori, T., Fukuoka, J., Oka, M., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0266 · Cited by 53
Anti-CTLA4 antibody clinical trials in melanoma
Ribas, A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.09.001 · Cited by 51
Self-citation
Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013
Suh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51

Authors: Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., Sharma, A., Glaspy, J. A., & Gomez-Navarro, J.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Medicine, Division of Hematology/Oncology; Surgery, Division of Surgical Oncology and UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, CA; Departments of Experimental Therapeutics, Melanoma Medical Oncology and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; and Pfizer Global Research and Development, Groton-New London, CT
ORCID: Ribas, Antoni
Camacho, Luis H.
Reuben, James M.
Sharma, Amarnath
Glaspy, John A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-12-10
Volume: 23
Issue: 35
Pages: 8968-8977
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.01.109
OpenAlex: W2163184777
Cited by: 591
References: 31
Citations by year: 2026: 4 · 2025: 1 · 2024: 11 · 2023: 18 · 2022: 19 · 2021: 21 · 2020: 24 · 2019: 29 · 2018: 24 · 2017: 32 · 2016: 33 · 2015: 29 · 2014: 25 · 2013: 38 · 2012: 27
FWCI: 22.08
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: American Society of Clinical Oncology
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: CTLA-4 blockade, melanoma, antitumor immunity, peripheral tolerance, autoimmune adverse events, maximum tolerated dose, dose-limiting toxicity, complete response, renal cell carcinoma, colon cancer, immunotherapy safety
MeSH terms: Adult, Aged, Antibodies, Monoclonal, Antibodies, Neoplasm, Antigens, Differentiation, Antigens, Neoplasm, Autoimmune Diseases, Colonic Neoplasms, Female, Humans, Immune Tolerance, Immunotherapy, Infusions, Intravenous, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Proteins, Neoplasms, Regression Analysis, Antigens, CD, T-Lymphocyte Subsets, Treatment Outcome, Antibodies, Blocking, Cancer Vaccines, MART-1 Antigen, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks